A Phase 2 interventional study of Axicabtagene Ciloleucel and Cyclophosphamide in Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Participants who completed at minimum 18 months follow up were transitioned to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
First submitted after Kite became part of Gilead Sciences.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
confirmed large B-cell lymphoma (LBCL), including the following types defined by World Health Organization (WHO) 2016 classification, by local pathology laboratory assessment, are eligible as defined below:
Individuals must have received adequate prior therapy including:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m\^2/day and fludarabine 30 mg/m\^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10\^6 cells/kg.
Biological: Axicabtagene Ciloleucel · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Dexamethasone
Administered intravenously
Also known as: Yescarta®
Administered intravenously
Administered intravenously
Administered orally or intravenously
Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity
CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death.
Time frame: Up to 2.2 years
Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity
Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death.
Time frame: Up to 2.2 years
Time to Onset of CRS Following Axicabtagene Ciloleucel Administration
Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses.
Time frame: Up to 2.2 years
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration
Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.
Time frame: Up to 2.2 years
Duration of CRS Following Axicabtagene Ciloleucel Administration
Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses.
Time frame: Up to 2.2 years
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration
Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.
Time frame: Up to 2.2 years
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion
Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts.
Time frame: Within 72 hours of axicabtagene ciloleucel infusion on Day 0
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion
Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion.
Time frame: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion
Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion.
Time frame: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion
Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion.
Time frame: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion
Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion.
Time frame: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
Time frame: Up to 2.2 years
Percentage of Intensive Care Unit (ICU) Admitted Participants
Time frame: Up to 30 days
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
Time frame: Up to 2.2 years
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion.
Time frame: Up to 2.2 years
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion.
Time frame: Up to 2.2 years
Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).
Time frame: Baseline, Week 4, Month 3, Month 6
EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score
The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).
Time frame: Baseline, Week 4, Month 3, Month 6
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
OR: complete response (complete metabolic response\[CMR\]; complete radiologic response\[CRR\]) or partial response (partial MR \[PMR\]; partial RR \[PRR\]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes \& extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by \>50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method.
Time frame: Up to 2.5 years
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off.
Time frame: Up to 2.5 years
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
Time frame: Up to 2.5 years
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
Time frame: Up to 2.5 years
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
Time frame: Up to 2.5 years
Overall Survival (OS)
OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses.
Time frame: Up to 2.5 years
Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Immune Effector Molecules: Perforin
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
Time frame: From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells
Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion.
Time frame: Up to 24 months
Participants were enrolled at study sites in the United States.
| Milestone | Axicabtagene Ciloleucel |
|---|---|
| Started | 35 |
| Completed | 0 |
| Not completed | 35 |
| Withdrew: Transition to the kt-us-982-5968 study | 19 |
| Withdrew: Death | 9 |
| Withdrew: Subject full withdrawal of consent from further follow-up | 3 |
| Withdrew: Investigator decision | 2 |
| Withdrew: Deep vein thrombosis | 1 |
| Withdrew: Expired cells | 1 |
CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Worst Grade 1 | 37 |
| Worst Grade 2 | 53 |
| Worst Grade 3 | 0 |
| Worst Grade 4 | 0 |
| Worst Grade 5 | 0 |
Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Worst Grade 1 | 30 |
| Worst Grade 2 | 27 |
| Worst Grade 3 | 20 |
| Worst Grade 4 | 3 |
| Worst Grade 5 | 0 |
Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses.
| days | Axicabtagene Ciloleucel |
|---|---|
| Time to Onset of CRS Following Axicabtagene Ciloleucel Administration | 4.0 (NA to NA) |
Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.
| days | Axicabtagene Ciloleucel |
|---|---|
| Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration | 7.0 (6.0 to 14.0) |
Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses.
| days | Axicabtagene Ciloleucel |
|---|---|
| Duration of CRS Following Axicabtagene Ciloleucel Administration | 5.0 (3.0 to 6.0) |
Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.
| days | Axicabtagene Ciloleucel |
|---|---|
| Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration | 5.5 (3.0 to 46.0) |
Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion | 37 |
Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion | 63 |
Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion | 90 |
Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion | 93 |
Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion | 93 |
| days | Axicabtagene Ciloleucel |
|---|---|
| Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion | 8 (2 to 44) |
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Admitted to ICU at any time | 13 |
| Admitted to ICU within 72 hours | 7 |
| Admitted to ICU within 4 days | 7 |
| Admitted to ICU within 7 days | 10 |
| Admitted to ICU within 14 days | 13 |
| Admitted to ICU within 30 days | 13 |
| days | Axicabtagene Ciloleucel |
|---|---|
| Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion | 7 (2 to 7) |
An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 100 |
A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs) | 80 |
The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).
| Participants | Axicabtagene Ciloleucel |
|---|---|
| Mobility: Baseline — No problems | 16 |
| Mobility: Baseline — Slight problems | 7 |
| Mobility: Baseline — Moderate problems | 1 |
| Mobility: Baseline — Severe problems | 0 |
| Mobility: Baseline — Extreme problems | 0 |
| Mobility: Week 4 — No problems | 15 |
| Mobility: Week 4 — Slight problems | 6 |
| Mobility: Week 4 — Moderate problems | 2 |
| Mobility: Week 4 — Severe problems | 1 |
| Mobility: Week 4 — Extreme problems | 0 |
| Mobility: Month 3 — No problems | 14 |
| Mobility: Month 3 — Slight problems | 4 |
| Mobility: Month 3 — Moderate problems | 3 |
| Mobility: Month 3 — Severe problems | 0 |
| Mobility: Month 3 — Extreme problems | 0 |
| Mobility: Month 6 — No problems | 12 |
| Mobility: Month 6 — Slight problems | 6 |
| Mobility: Month 6 — Moderate problems | 0 |
| Mobility: Month 6 — Severe problems | 0 |
| Mobility: Month 6 — Extreme problems | 0 |
| Self-Care: Baseline — No problems | 22 |
| Self-Care: Baseline — Slight problems | 1 |
| Self-Care: Baseline — Moderate problems | 1 |
| Self-Care: Baseline — Severe problems | 0 |
| Self-Care: Baseline — Extreme problems | 0 |
| Self-Care: Week 4 — No problems | 18 |
| Self-Care: Week 4 — Slight problems | 5 |
| Self-Care: Week 4 — Moderate problems | 0 |
| Self-Care: Week 4 — Severe problems | 1 |
| Self-Care: Week 4 — Extreme problems | 0 |
| Self-Care: Month 3 — No problems | 18 |
| Self-Care: Month 3 — Slight problems | 2 |
| Self-Care: Month 3 — Moderate problems | 1 |
| Self-Care: Month 3 — Severe problems | 0 |
| Self-Care: Month 3 — Extreme problems | 0 |
| Self-Care: Month 6 — No problems | 15 |
| Self-Care: Month 6 — Slight problems | 3 |
| Self-Care: Month 6 — Moderate problems | 0 |
| Self-Care: Month 6 — Severe problems | 0 |
| Self-Care: Month 6 — Extreme problems | 0 |
| Usual Activity: Baseline — No problems | 16 |
| Usual Activity: Baseline — Slight problems | 6 |
| Usual Activity: Baseline — Moderate problems | 1 |
| Usual Activity: Baseline — Severe problems | 1 |
| Usual Activity: Baseline — Extreme problems | 0 |
| Usual Activity: Week 4 — No problems | 10 |
| Usual Activity: Week 4 — Slight problems | 6 |
| Usual Activity: Week 4 — Moderate problems | 4 |
| Usual Activity: Week 4 — Severe problems | 3 |
| Usual Activity: Week 4 — Extreme problems | 1 |
| Usual Activity: Month 3 — No problems | 8 |
| Usual Activity: Month 3 — Slight problems | 6 |
| Usual Activity: Month 3 — Moderate problems | 5 |
| Usual Activity: Month 3 — Severe problems | 2 |
| Usual Activity: Month 3 — Extreme problems | 0 |
| Usual Activity: Month 6 — No problems | 12 |
| Usual Activity: Month 6 — Slight problems | 4 |
| Usual Activity: Month 6 — Moderate problems | 2 |
| Usual Activity: Month 6 — Severe problems | 0 |
| Usual Activity: Month 6 — Extreme problems | 0 |
| Pain / Discomfort: Baseline — No problems | 12 |
| Pain / Discomfort: Baseline — Slight problems | 8 |
| Pain / Discomfort: Baseline — Moderate problems | 2 |
| Pain / Discomfort: Baseline — Severe problems | 2 |
| Pain / Discomfort: Baseline — Extreme problems | 0 |
| Pain / Discomfort: Week 4 — No problems | 13 |
| Pain / Discomfort: Week 4 — Slight problems | 4 |
| Pain / Discomfort: Week 4 — Moderate problems | 6 |
| Pain / Discomfort: Week 4 — Severe problems | 1 |
| Pain / Discomfort: Week 4 — Extreme problems | 0 |
| Pain / Discomfort: Month 3 — No problems | 8 |
| Pain / Discomfort: Month 3 — Slight problems | 4 |
| Pain / Discomfort: Month 3 — Moderate problems | 7 |
| Pain / Discomfort: Month 3 — Severe problems | 2 |
| Pain / Discomfort: Month 3 — Extreme problems | 0 |
| Pain / Discomfort: Month 6 — No problems | 7 |
| Pain / Discomfort: Month 6 — Slight problems | 6 |
| Pain / Discomfort: Month 6 — Moderate problems | 5 |
| Pain / Discomfort: Month 6 — Severe problems | 0 |
| Pain / Discomfort: Month 6 — Extreme problems | 0 |
| Anxiety / Depression: Baseline — No problems | 12 |
| Anxiety / Depression: Baseline — Slight problems | 8 |
| Anxiety / Depression: Baseline — Moderate problems | 4 |
| Anxiety / Depression: Baseline — Severe problems | 0 |
| Anxiety / Depression: Baseline — Extreme problems | 0 |
| Anxiety / Depression: Week 4 — No problems | 14 |
| Anxiety / Depression: Week 4 — Slight problems | 3 |
| Anxiety / Depression: Week 4 — Moderate problems | 4 |
| Anxiety / Depression: Week 4 — Severe problems | 2 |
| Anxiety / Depression: Week 4 — Extreme problems | 1 |
| Anxiety / Depression: Month 3 — No problems | 7 |
| Anxiety / Depression: Month 3 — Slight problems | 9 |
| Anxiety / Depression: Month 3 — Moderate problems | 3 |
| Anxiety / Depression: Month 3 — Severe problems | 1 |
| Anxiety / Depression: Month 3 — Extreme problems | 1 |
| Anxiety / Depression: Month 6 — No problems | 11 |
| Anxiety / Depression: Month 6 — Slight problems | 5 |
| Anxiety / Depression: Month 6 — Moderate problems | 1 |
| Anxiety / Depression: Month 6 — Severe problems | 1 |
| Anxiety / Depression: Month 6 — Extreme problems | 0 |
The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health. Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).
| score on a scale | Axicabtagene Ciloleucel |
|---|---|
| Baseline | 76.6 ± 20.31 |
| Week 4 | 75.8 ± 19.18 |
| Month 3 | 79.8 ± 13.97 |
| Month 6 | 82.5 ± 11.66 |
OR: complete response (complete metabolic response\[CMR\]; complete radiologic response\[CRR\]) or partial response (partial MR \[PMR\]; partial RR \[PRR\]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes \& extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by \>50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma | 93 (77.2 to 99.2) |
Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off.
| percentage of participants | Axicabtagene Ciloleucel |
|---|---|
| Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma | 76 (56.5 to 89.7) |
DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
| months | Axicabtagene Ciloleucel |
|---|---|
| Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma | NA (3.0 to NA) |
PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
| months | Axicabtagene Ciloleucel |
|---|---|
| Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma | NA (3.8 to NA) |
EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi \>1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by \> 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.
| months | Axicabtagene Ciloleucel |
|---|---|
| Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma | NA (3.8 to NA) |
OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses.
| months | Axicabtagene Ciloleucel |
|---|---|
| Overall Survival (OS) | NA (NA to NA) |
Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28.
| picograms per milliliter (pg/mL) | Axicabtagene Ciloleucel |
|---|---|
| IL-2 | 27.15 (13.70 to 44.70) |
| IL-7 | 31.70 (27.60 to 42.40) |
| IL-15 | 40.40 (29.00 to 58.00) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| pg/mL | Axicabtagene Ciloleucel |
|---|---|
| IFN-γ | 431.95 (173.10 to 1522.20) |
| IL-1 | NA (NA to NA) |
| IL-6 | 211.00 (69.70 to 737.10) |
| IL-13 | NA (NA to NA) |
| IL-17 | 9.30 (9.30 to 27.55) |
| IL-1RA | 2033.50 (940.00 to 5457.00) |
| GM-CSF | 4.60 (1.90 to 9.60) |
| TNF-α | 4.35 (3.00 to 7.70) |
| IL-12p40 | 160.50 (111.60 to 254.00) |
| IL-12p70 | 1.20 (1.20 to 1.20) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| pg/mL | Axicabtagene Ciloleucel |
|---|---|
| Granzyme A | 346.00 (270.00 to 478.00) |
| Granzyme B | 96.70 (56.60 to 147.00) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| nanograms per milliliter (ng/mL) | Axicabtagene Ciloleucel |
|---|---|
| Peak Serum Levels of Immune Effector Molecules: Perforin | 8.81 (5.78 to 16.38) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| pg/mL | Axicabtagene Ciloleucel |
|---|---|
| Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA) | 817000000 (308000000 to 1380000000) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| milligrams per liter (mg/L) | Axicabtagene Ciloleucel |
|---|---|
| Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP) | 115.44 (67.47 to 409.41) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| ng/mL | Axicabtagene Ciloleucel |
|---|---|
| Peak Serum Levels of the Acute Phase Response Proteins: Ferritin | 997.87 (433.59 to 2535.89) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| ng/mL | Axicabtagene Ciloleucel |
|---|---|
| Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα) | 11.67 (6.62 to 23.68) |
Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.
| pg/mL | Axicabtagene Ciloleucel |
|---|---|
| IL-8 | 73.90 (34.10 to 205.60) |
| CXCL-10 | 2000.00 (1316.00 to 2000.00) |
| MCP-1 | 1251.00 (865.30 to 1500.00) |
Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion.
| cells per microliter (cells/μL) | Axicabtagene Ciloleucel |
|---|---|
| Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells | 40.84 (30.54 to 68.89) |
Collected over All-Cause Mortality: Up to 2.5 years; Adverse Events: Up to 2.2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axicabtagene Ciloleucel | 9/35 (25.7%) | 24/30 (80%) | 29/30 (96.7%) |
| Event | Axicabtagene Ciloleucel |
|---|---|
| PyrexiaGeneral disorders | 18/30 |
| Confusional statePsychiatric disorders | 6/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/30 |
| AphasiaNervous system disorders | 3/30 |
| HypotensionVascular disorders | 3/30 |
| B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/30 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 1/30 |
| ArrhythmiaCardiac disorders | 1/30 |
| Large intestine perforationGastrointestinal disorders | 1/30 |
| AstheniaGeneral disorders | 1/30 |
| Event | Axicabtagene Ciloleucel |
|---|---|
| HypotensionVascular disorders | 16/30 |
| PyrexiaGeneral disorders | 14/30 |
| ChillsGeneral disorders | 13/30 |
| Neutrophil count decreasedInvestigations | 12/30 |
| FatigueGeneral disorders | 11/30 |
| Platelet count decreasedInvestigations | 11/30 |
| HeadacheNervous system disorders | 11/30 |
| White blood cell count decreasedInvestigations | 9/30 |
| Confusional statePsychiatric disorders | 9/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/30 |
The Safety Analysis Set included all participants who were treated with any dose of axicabtagene ciloleucel.
| Age, Categorical(Participants) | Axicabtagene Ciloleucel |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 11 |
| Age, Continuous(years) | Axicabtagene Ciloleucel |
|---|---|
| Mean | 60 ± 13.1 |
| Sex: Female, Male(Participants) | Axicabtagene Ciloleucel |
|---|---|
| Female | 10 |
| Male | 20 |
| Race/Ethnicity, Customized(Participants) | Axicabtagene Ciloleucel |
|---|---|
| Race — White | 22 |
| Race — Asian | 3 |
| Race — Black or African American | 2 |
| Race — Other or More Than One Race | 1 |
| Race — Not Collected | 2 |
| Race/Ethnicity, Customized(Participants) | Axicabtagene Ciloleucel |
|---|---|
| Ethnicity — Not Hispanic or Latino | 23 |
| Ethnicity — Not Collected | 5 |
| Ethnicity — Hispanic or Latino | 2 |
| Region of Enrollment(Participants) | Axicabtagene Ciloleucel |
|---|---|
| United States | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Aug 2022 to primary completion in Nov 2025, 39 months.
Results were first posted in Nov 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axicabtagene ciloleucel